<DOC>
	<DOCNO>NCT01657526</DOCNO>
	<brief_summary>The purpose study evaluate safety , reactogenicity immunogenicity GSK Biologicals ' NTHi candidate vaccine adult , administer first time human .</brief_summary>
	<brief_title>Safety , Reactogenicity Immunogenicity GlaxoSmithKline ( GSK ) Biologicals ' Non-typeable Haemophilus Influenzae ( NTHI ) Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Respiration Disorders</mesh_term>
	<mesh_term>Respiratory Tract Diseases</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects , opinion investigator , comply requirement protocol . Written inform consent obtain subject . A male female , include , 18 40 year age time first vaccination . Healthy subject establish medical history , physical examination laboratory assessment enter study . Female subject nonchildbearing potential may enrol study . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination series . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine , plan use study period . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational vaccine/product . Planned administration/administration vaccine/product foreseen study protocol period start 30 day first vaccine dose end 30 day last dose vaccine . Previous vaccination vaccine contain NTHi antigen . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose , equivalent . Topical steroid allow . Administration immunoglobulins and/or blood product within 3 month precede first dose study vaccine plan administration study period . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Laboratory evidence clinically significant haematological ( complete blood cell count [ Red Blood Cells ( RBC ) , White Blood Cells ( WBC ) ] , WBC differential count , platelet count haemoglobin level ) biochemical ( Alanine Aminotransferase [ ALT ] , Aspartate Aminotransferase [ AST ] , creatinine lactate dehydrogenase [ LDH ] ) abnormalities per opinion investigator base local laboratory normative data . Acute disease and/or fever time enrolment . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screen test . History current condition prevent intramuscular injection bleed coagulation disorder . Malignancies within previous 5 year ( exclude nonmelanic skin cancer ) lymphoproliferative disorder . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution . History chronic alcohol consumption and/or drug abuse . Any condition investigator judge may interfere study finding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Healthy adult</keyword>
	<keyword>Safety</keyword>
	<keyword>Reactogenicity</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Non-typeable H. Influenzae ( NTHi )</keyword>
</DOC>